SCHEMBL3147604

SCHEMBL3147604

CCCN(CCC)CCc1c[nH]c2ccc(NS(=O)(=O)c3sc4ccc(Cl)cc4c3C)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 1.00
CMA1 P23946 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
PFKFB3 Q16875 2/20 0.49
PFKFB4 Q16877 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3156507 0.95 HTR6 (0.91) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL3145090 0.94 HTR6 (1.00) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL3148370 0.91 HTR6 (1.00) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL3147252 0.89 HTR6 (0.90) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL4969770 0.87 HTR6 (0.78) HTR6
SCHEMBL1575827 0.87 HTR6 (0.87) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL1997328 0.87 HTR6 (0.80) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL1998470 0.86 HTR6 (0.77) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL1999791 0.86 HTR6 (0.79) HTR6CMA1NPSR1L3MBTL1PFKFB3
SCHEMBL3152564 0.85 HTR6 (1.00) HTR6CMA1NPSR1L3MBTL1PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081600-B1 Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity ESTEVE LABOR DR (ES) 2012-12-05 EP claimed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US claimed
US-7498328-B2 Derivatives of sulphonamides, their preparation and use as medicaments LABORATORIAS DEL DR. ESTEVE, S.A. (ES) 2009-03-03 US claimed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP claimed
WO-2009013010-A2 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-01-29 WO claimed
EP-2018861-A1 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain Laboratorios del Dr. Esteve S.A. (ES) 2009-01-28 EP claimed
EP-1626715-B1 USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION ESTEVE LABOR DR (ES) 2008-09-10 EP claimed
US-20060258653-A1 Derivatives of sulphonamides, their preparation and use as medicaments MERCE-VIDAL RAMON 2006-11-16 US claimed
JP-2006525972-A 2006-11-16 JP claimed
EP-1445252-B1 SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS ESTEVE LABOR DR (ES) 2006-03-08 EP claimed
EP-1626715-A1 USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-02-22 EP claimed
US-20050065202-A1 Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2005-03-24 US claimed
WO-2004098588-A1 USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2004-11-18 WO claimed
EP-1445252-A1 SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2004-08-11 EP claimed
US-20030191124-A1 Derivatives of sulphonamides, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2003-10-09 US claimed
EP-2081600-B1 Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity ESTEVE LABOR DR (ES) 2012-12-05 EP disclosed
US-20120128768-A1 ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY LABORATORIOS DEL DR. ESTEVE S.A (ES) 2012-05-24 US disclosed
WO-2004098588-A1 USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2004-11-18 WO disclosed
EP-1445252-A1 SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2004-08-11 EP disclosed
US-20030191124-A1 Derivatives of sulphonamides, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2003-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065202-A1 Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion SULT2A1, STS, MPST HTR6 886/4885CMA1 198/4885NPSR1 189/4885
US-20090264457-A1 Combination of at least two 5HT6-Ligands HTR6, HTR3B, HTR4 HTR6 1/4885CMA1 835/4885NPSR1 88/4885
US-20120128768-A1 ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY HTR6, NPY5R, NPY2R HTR6 1/4885CMA1 472/4885NPSR1 5/4885
US-20060258653-A1 Derivatives of sulphonamides, their preparation and use as medicaments STS, SULT2A1, MPST HTR6 3170/4885CMA1 843/4885NPSR1 663/4885
US-20030191124-A1 Derivatives of sulphonamides, their preparation and use as medicaments STS, SULT2A1, MPST HTR6 3229/4885CMA1 779/4885NPSR1 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.